NCT05624840 is a clinical trial of Nirmatrelvir/ritonavir in COVID-19, sponsored by Chinese University of Hong Kong.

Who is sponsoring NCT05624840?

NCT05624840 is sponsored by Chinese University of Hong Kong.

What drugs are being tested in NCT05624840?

Interventions in NCT05624840: Nirmatrelvir/ritonavir.

What condition does NCT05624840 study?

NCT05624840 studies COVID-19, Chronic Kidney Disease stage4, Chronc Kidney Disease Stage 5.

Is NCT05624840 still recruiting?

NCT05624840 is currently completed. Last updated 7 February 2024.

Last reviewed 2024-02-07 · How we verify

NCT05624840

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir

Completed Last updated 7 February 2024

What this trial tests

trial testing Nirmatrelvir/ritonavir in COVID-19 in 85 participants. Completed in 1 February 2023.

Timeline

7 November 2022

Primary endpoint
31 January 2023

1 February 2023

Quick facts

Lead sponsor	Chinese University of Hong Kong
Status	Completed
Study type	OBSERVATIONAL
Enrollment	85
Start date	7 November 2022
Primary completion	31 January 2023
Estimated completion	1 February 2023
Sites	1 location across Hong Kong

Drugs / interventions tested

Nirmatrelvir/ritonavir

Conditions studied

COVID-19 — all drugs for COVID-19 →
Chronic Kidney Disease stage4 — all drugs for Chronic Kidney Disease stage4 →
Chronc Kidney Disease Stage 5 — all drugs for Chronc Kidney Disease Stage 5 →

Sponsor

Chinese University of Hong Kong

Who can join

18 and older, any sex, with COVID-19 or Chronic Kidney Disease stage4. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Nirmatrelvir-ritonavir is approved for coronavirus disease 2019 (COVID-19) but not initially recommended in patients with severe renal impairment. Increasing observational data have shown the feasibility of dose-adjusted nirmatrelvir-ritonavir administration in patients with estimated glomerular filtration rate lower than 30 ml/min/1.73 m\^2. The study is planned to assess the safety, clinical and virologic outcomes of early oral nirmatrevir-ritonavir treatment of COVID-19 in patients with stage 4 and 5 chronic kidney disease.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Drug treatment of COVID-19 infection.
Lui G, Guaraldi G. · · 2023 · cited 27× · PMID 36917228 · DOI 10.1097/mcp.0000000000000953
Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019.
Chan GCK, Lui GCY, Wong CNS, Yip SST, et al · · 2023 · cited 12× · PMID 37531093 · DOI 10.1093/cid/ciad371

Verify or expand the search:

Other trials of Nirmatrelvir/ritonavir

Trials testing the same drug.

NCT06397144 — A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Heal · Phase 1 · withdrawn
NCT05938140 — Efficiency and Safety of Paxlovid for COVID-19 Patients With Severe Chronic Kidney Disease · Phase 4 · unknown
NCT05898672 — A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administ · Phase 1 · completed
NCT05852873 — PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway · Phase 3 · active not recruiting
NCT05823896 — ImPROving Quality of LIFe in the Long COVID Patient · Phase 2 · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05624840 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
Last refreshed: 7 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05624840.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing